PD-1抑制剂,卡瑞丽珠单抗,大疱性类天疱疮," /> PD-1抑制剂,卡瑞丽珠单抗,大疱性类天疱疮,"/> PD-1 inhibitors, camrelizumab, bullous pemphigoid,"/> Bullous pemphigoid occurred after long-term treatment with camrelizumab in a patient with oesophageal cancer: a case report

China Journal of Leprosy and Skin Diseases ›› 2024, Vol. 40 ›› Issue (6): 422-424.doi: 10.12144/zgmfskin202406422

• Clinical Researches • Previous Articles     Next Articles

Bullous pemphigoid occurred after long-term treatment with camrelizumab in a patient with oesophageal cancer: a case report

ZHENG Chunzhi1,2, ZHANG Minkuo1,2, SAI Wenwen1,2, CAO Yuanyuan1,2, ZHANG Zhaoxia1,2, PAN Futang1,2, YANG Baoqi1,2, LIU Hong1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2024-06-15 Published:2024-05-08

PDF (PC)

154

Like

Abstract: Immune checkpoint inhibitors (ICIs) have brought about a disruptive change in the treatment of tumours, but have also led to a higher incidence of immune-related adverse events (irAEs). Among them, bullous pemphigoid (BP) is a rare irAE, which is mainly manifested by blisters with tense blister based on erythema. In this paper, we report a case of BP occurring after long-term treatment with camerelizumab and summarise the diagnosis and treatment strategy of ICI-induced BP.

Key words: PD-1 inhibitors')">">PD-1 inhibitors, camrelizumab, bullous pemphigoid